Clinical trial · Observational
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples. NGS panel detection and WGD/AS analysis were performed on the tissue. Paracancer tissue was used as a negative control and relevant information in medical records during the operation. Then we will collect clinical diagnosis and disease information through telephone follow-up after the completion of the operation.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chromosomal Instability | — | UNRESOLVED | — |
| Endometrial Neoplasms | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Microsatellite Stable Endometrial Carcinoma | Microsatellite Stable Endometrial Carcinoma | ONTOLOGY_EXACT | 0.98 |
| TP53 Gene Mutation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- microsatellite stability status
- timeFrame
- 2025-06-30
- description
- microsatellite stability status
- measure
- TP53 mutation
- timeFrame
- 2025-06-30
- description
- TP53 mutation
- measure
- Chromosomal instability
- timeFrame
- 2025-06-30
- description
- Chromosomal instability (Whole genome duplication, Aneuploidy)
Secondary outcomes (1)
- measure
- recurrence
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * willing to participate in the study and sign the informed consent * age ≥18 years old * researchers evaluated that it was suitable to participate in this translational study * Endometrial cancer was confirmed histologically * histopathological molecular classification was consistent with pMMR type and POLE wild type * The tumor tissue obtained by operation was the primary lesion Exclusion Criteria: * Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection * previously treated with KIF18A inhibitors * researchers believed that the subjects were not suitable for the translational study for other reasons
References
Publications (0)
Data not yet available